CSF proteomics analysis to investigate the pharmacodynamic response of the S2R modulator CT1812 in Alzheimer’s disease patients from the SPARC clinical trial

CT1812 is an investigational therapeutic that can displace toxic amyloid‐beta oligomers from neuronal receptors and is currently in development for Alzheimer’s disease (AD). SPARC (COG0105; NCT03493282), was a randomized double‐blinded placebo‐controlled clinical trial designed to test the impact of the small molecule sigma‐2 receptor (S2R) modulator CT1812 on safety and synaptic density. Exploratory analyses included discovery proteomics for pharmacodynamic biomarker identification and to understand the impact of CT1812 on CSF proteins detected in mild to moderate AD patients.